130 related articles for article (PubMed ID: 1754634)
1. Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients.
Chang WH; Hwu HG; Lane HY; Lin SK; Chen TY; Chen H; Wei HL; Lin WL; Lin HN
Psychiatry Res; 1991 Sep; 38(3):215-25. PubMed ID: 1754634
[TBL] [Abstract][Full Text] [Related]
2. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
3. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
Chang WH; Lin SK; Jann MW
J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
[TBL] [Abstract][Full Text] [Related]
4. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.
Pan L; Vander Stichele R; Rosseel MT; Berlo JA; De Schepper N; Belpaire FM
Ther Drug Monit; 1999 Oct; 21(5):489-97. PubMed ID: 10519444
[TBL] [Abstract][Full Text] [Related]
5. Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?
Chang WH
Psychopharmacology (Berl); 1992; 106(3):289-96. PubMed ID: 1570373
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
Chang WH; Lin SK; Jann MW; Lam YW; Chen TY; Chen CT; Hu WH; Yeh EK
Biol Psychiatry; 1989 Jul; 26(3):239-49. PubMed ID: 2742942
[TBL] [Abstract][Full Text] [Related]
7. [The plasma levels of haloperidol and reduced haloperidol in Japanese psychiatric patients].
Someya T; Shibasaki M; Takahashi S
Yakubutsu Seishin Kodo; 1989 Jun; 9(2):207-15. PubMed ID: 2816093
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population.
Someya T; Shimoda K; Suzuki Y; Sato S; Kawashima Y; Hirokane G; Morita S; Yokono A; Takahashi S
Neuropsychopharmacology; 2003 Aug; 28(8):1501-5. PubMed ID: 12784098
[TBL] [Abstract][Full Text] [Related]
9. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction.
Someya T; Shibasaki M; Noguchi T; Takahashi S; Inaba T
J Clin Psychopharmacol; 1992 Jun; 12(3):169-74. PubMed ID: 1629382
[TBL] [Abstract][Full Text] [Related]
10. Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients.
Someya T; Takahashi S; Shibasaki M; Inaba T; Cheung SW; Tang SW
Psychiatry Res; 1990 Feb; 31(2):111-20. PubMed ID: 2326392
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs.
Chang WH; Jaw SS; Wu HS; Tsay L; Yeh EK
Psychopharmacology (Berl); 1988; 96(3):285-8. PubMed ID: 3146762
[TBL] [Abstract][Full Text] [Related]
12. Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American non-Chinese.
Chang WH; Jann MW; Hwu HG; Chen TY; Lin SK; Wang JM; Ereshefsky L; Saklad SR; Richards AL; Lam YW
J Formos Med Assoc; 1991 Jun; 90(6):572-8. PubMed ID: 1681004
[TBL] [Abstract][Full Text] [Related]
13. Relation of plasma and red blood cells reduced haloperidol concentrations to haloperidol reductase activity assayed in red blood cells in psychiatric population.
Shibasaki M; Someya T; Takahashi S
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):257-67. PubMed ID: 8430218
[TBL] [Abstract][Full Text] [Related]
14. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
[TBL] [Abstract][Full Text] [Related]
15. Interconversion between haloperidol and reduced haloperidol in healthy volunteers.
Chakraborty BS; Hubbard JW; Hawes EM; McKay G; Cooper JK; Gurnsey T; Korchinski ED; Midha KK
Eur J Clin Pharmacol; 1989; 37(1):45-8. PubMed ID: 2591462
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two high-performance liquid chromatographic methods for monitoring plasma concentrations of haloperidol and reduced haloperidol.
Pan L; Rosseel MT; Belpaire FM
Ther Drug Monit; 1998 Apr; 20(2):224-30. PubMed ID: 9558139
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid.
Aymard N; Viala A; Stein I; Caroli F
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1119-35. PubMed ID: 8787036
[TBL] [Abstract][Full Text] [Related]
18. Comparison of haloperidol plasma concentrations between twice-a-day and once-a-day dosing in Chinese schizophrenic patients.
Lin SK; Chen CH; Chang WH
J Formos Med Assoc; 1993 Sep; 92(9):832-4. PubMed ID: 7904867
[TBL] [Abstract][Full Text] [Related]
19. Splanchnic uptake of haloperidol and release of reduced haloperidol in vivo in the guinea pig.
Huang MT; Ho LS; Juang DJ; Chang WH; Yang YY
Biochem Pharmacol; 1992 Aug; 44(3):601-4. PubMed ID: 1510709
[TBL] [Abstract][Full Text] [Related]
20. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP
Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
